From Reactive to Proactive Care: Using AI to Detect Gender-Based Violence in Brazil - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Using AI to Identify Gender-Based Violence in Brazilian Health Records and Enable Earlier Intervention

  • By

  • Luke Taylor

  • October 19, 2026

Share

Objective:

The article describes ClarIA, an AI tool designed to identify possible indicators of gender-based violence (GBV) in Brazilian health records, and reports on its pilot analysis and early deployment in Recife.

Approach:
  • Pilot analysis: Vital Strategies and the Federal University of Juiz de Fora analyzed 13,000 formally documented GBV cases in Recife.
  • Detection: ClarIA analyzes clinical notes and medical histories for semantic patterns resembling records of confirmed GBV cases; it does not rely on isolated keywords.
  • Alerts and response: Amber alerts flag patterns of signs, symptoms, and complaints associated with confirmed cases. Red alerts concern prior disclosure or identification of violence. Trained clinicians receive guidance on sensitive follow-up.
Key Findings:
  • In the pilot, women’s clinic visits began an average of 92 days before GBV was recorded in their cases.
  • Records showed patterns including increased headache complaints and mental health problems; many women did not explicitly disclose violence during visits.
  • After deployment began in Recife in March, ClarIA operated across 39 clinics and hospitals. Health professionals submitted eight GBV notifications after receiving alerts.
  • Women whose assaults were not formally notified faced an eightfold greater risk of death than women with reported assaults.
  • Among femicide victims identified by linking violence and mortality records, more than 60% died within 30 days after a GBV notification.
Interpretation:

ClarIA alerts are prompts for clinicians to examine potential clinical, psychosomatic, and social indicators of violence; they are not diagnoses.

Limitations:
  • The program is new, and available data remain limited.
  • The article describes a pilot and early deployment; it does not report a controlled evaluation of ClarIA’s effect on violence or mortality.
Conclusion:

ClarIA is being deployed across clinics and hospitals in Recife to flag possible GBV indicators in health records and prompt trained clinicians to assess patients sensitively.

Sources:

Original Source(s)

Related Content